Ilyang Pharm Stock Fundamentals
| 007570 Stock | 11,300 80.00 0.71% |
Ilyang Pharm fundamentals help investors to digest information that contributes to Ilyang Pharm's financial success or failures. It also enables traders to predict the movement of Ilyang Stock. The fundamental analysis module provides a way to measure Ilyang Pharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ilyang Pharm stock.
Ilyang |
Ilyang Pharm Company Current Valuation Analysis
Ilyang Pharm's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Ilyang Pharm Current Valuation | 396.95 B |
Most of Ilyang Pharm's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ilyang Pharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Ilyang Pharm has a Current Valuation of 396.95 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all Republic of Korea stocks is notably lower than that of the firm.
Ilyang Pharm Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ilyang Pharm's current stock value. Our valuation model uses many indicators to compare Ilyang Pharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ilyang Pharm competition to find correlations between indicators driving Ilyang Pharm's intrinsic value. More Info.Ilyang Pharm is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.48 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Ilyang Pharm is roughly 2.08 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Ilyang Pharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Ilyang Pharm's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Ilyang Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ilyang Pharm's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ilyang Pharm could also be used in its relative valuation, which is a method of valuing Ilyang Pharm by comparing valuation metrics of similar companies.Ilyang Pharm is currently under evaluation in current valuation category among its peers.
Ilyang Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0597 | |||
| Profit Margin | 0.05 % | |||
| Operating Margin | 0.12 % | |||
| Current Valuation | 396.95 B | |||
| Shares Outstanding | 18.09 M | |||
| Shares Owned By Insiders | 26.59 % | |||
| Shares Owned By Institutions | 3.74 % | |||
| Price To Book | 1.56 X | |||
| Price To Sales | 0.96 X | |||
| Revenue | 371.35 B | |||
| Gross Profit | 204.29 B | |||
| EBITDA | 53.64 B | |||
| Net Income | 14.38 B | |||
| Total Debt | 5.02 B | |||
| Cash Flow From Operations | 67.02 B | |||
| Target Price | 44000.0 | |||
| Number Of Employees | 675 | |||
| Beta | -0.0491 | |||
| Market Capitalization | 345.28 B | |||
| Total Asset | 494.27 B | |||
| Z Score | 40.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 494.27 B | |||
| Last Dividend Paid | 150.0 |
About Ilyang Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ilyang Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ilyang Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ilyang Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Ilyang Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ilyang Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ilyang Pharm will appreciate offsetting losses from the drop in the long position's value.Moving together with Ilyang Stock
| 0.78 | 005935 | Samsung Electronics | PairCorr |
| 0.81 | 005930 | Samsung Electronics | PairCorr |
| 0.67 | 005490 | POSCO Holdings | PairCorr |
Moving against Ilyang Stock
The ability to find closely correlated positions to Ilyang Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ilyang Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ilyang Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ilyang Pharm to buy it.
The correlation of Ilyang Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ilyang Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ilyang Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ilyang Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Ilyang Stock
Ilyang Pharm financial ratios help investors to determine whether Ilyang Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ilyang with respect to the benefits of owning Ilyang Pharm security.